Genmab — Januar 2021
-
-
Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. "Our notable full year performance reflects the...
(www.prnewswire.com)
-
US surprisingly high - RoW surprisingly low
-
Thanks, ROW a bit dissapoiting
-
fun fact - in Q3 the prescription/sales ratio was 88%. In Q4 the ratio was 92%
-
Faspro must be selling without discount
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind